MErCuRIC1: A phase 1a study of MEK1/2 inhibitor PD-0325901 with cMET inhibitor crizotinib in patients with advanced solid tumours

• Autoři: WILSON R; MIDDLETON MR; HOULDEN J; VAN Schaeybroeck S; ROLFO CD; ELEZ E; TAIEB J; ANDRE T; BARDELLI A; LAURENT-PUIG P; TABERNERO J; PEETERS M; MAUGHAN T; ROBERTS C; LOVE S; LAWLER M; SALTO-TELLEZ M; GRAYSON M; POPOVICI Vlad; DI Nicolantonio F
• Rok publikování: 2016
• Druh: Konferenční abstrakty